Last reviewed · How we verify
Desogestrel and Ethinyl Estradiol Tablets
At a glance
| Generic name | Desogestrel and Ethinyl Estradiol Tablets |
|---|---|
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- Desogestrel-containing COCP Pharmacokinetic Validation Study (PHASE4)
- Assessing the Impact of Contraceptives on Bone Health Using 41Ca (PHASE4)
- Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding (NA)
- A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives (PHASE1)
- A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021 (PHASE3)
- Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam (PHASE1)
- NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: